These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

168 related items for PubMed ID: 9916607

  • 1. Efficacy, tolerability, and effects on quality of life of inhaled salmeterol and oral theophylline in patients with mild-to-moderate chronic obstructive pulmonary disease. SLMT02 Italian Study Group.
    Di Lorenzo G, Morici G, Drago A, Pellitteri ME, Mansueto P, Melluso M, Norrito F, Squassante L, Fasolo A.
    Clin Ther; 1998; 20(6):1130-48. PubMed ID: 9916607
    [Abstract] [Full Text] [Related]

  • 2. Comparison of inhaled salmeterol and individually dose-titrated slow-release theophylline in patients with reversible airway obstruction. European Study Group.
    Paggiaro PL, Giannini D, Di Franco A, Testi R.
    Eur Respir J; 1996 Aug; 9(8):1689-95. PubMed ID: 8866596
    [Abstract] [Full Text] [Related]

  • 3. A comparison between inhaled salmeterol and theophylline in the short-term treatment of stable chronic obstructive pulmonary disease.
    Broseghini C, Testi R, Polese G, Tosatto R, Rossi A.
    Pulm Pharmacol Ther; 2005 Aug; 18(2):103-8. PubMed ID: 15649852
    [Abstract] [Full Text] [Related]

  • 4. Salmeterol versus slow-release theophylline in patients with reversible obstructive pulmonary disease.
    Taccola M, Bancalari L, Ghignoni G, Paggiaro PL.
    Monaldi Arch Chest Dis; 1999 Aug; 54(4):302-6. PubMed ID: 10546469
    [Abstract] [Full Text] [Related]

  • 5. Additive effects of salmeterol and fluticasone or theophylline in COPD.
    Cazzola M, Di Lorenzo G, Di Perna F, Calderaro F, Testi R, Centanni S.
    Chest; 2000 Dec; 118(6):1576-81. PubMed ID: 11115442
    [Abstract] [Full Text] [Related]

  • 6. Salmeterol plus theophylline combination therapy in the treatment of COPD.
    ZuWallack RL, Mahler DA, Reilly D, Church N, Emmett A, Rickard K, Knobil K.
    Chest; 2001 Jun; 119(6):1661-70. PubMed ID: 11399688
    [Abstract] [Full Text] [Related]

  • 7. Inhaled salmeterol: a review of its efficacy in chronic obstructive pulmonary disease.
    Jarvis B, Markham A.
    Drugs Aging; 2001 Jun; 18(6):441-72. PubMed ID: 11419918
    [Abstract] [Full Text] [Related]

  • 8. Salmeterol vs theophylline: sleep and efficacy outcomes in patients with nocturnal asthma.
    Wiegand L, Mende CN, Zaidel G, Zwillich CW, Petrocella VJ, Yancey SW, Rickard KA.
    Chest; 1999 Jun; 115(6):1525-32. PubMed ID: 10378544
    [Abstract] [Full Text] [Related]

  • 9. Long-term treatment of asthmatic patients with salmeterol vs slow-release theophylline.
    Nutini S, Martini T, Righi R.
    Respir Med; 1998 Apr; 92(4):683-90. PubMed ID: 9659537
    [Abstract] [Full Text] [Related]

  • 10. Salmeterol & fluticasone 50 microg/250 microg bid in combination provides a better long-term control than salmeterol 50 microg bid alone and placebo in COPD patients already treated with theophylline.
    Dal Negro RW, Pomari C, Tognella S, Micheletto C.
    Pulm Pharmacol Ther; 2003 Apr; 16(4):241-6. PubMed ID: 12850128
    [Abstract] [Full Text] [Related]

  • 11. Efficacy and tolerability of fluticasone propionate/salmeterol administered twice daily via hydrofluoroalkane 134a metered-dose inhaler in adolescent and adult patients with persistent asthma: a randomized, double-blind, placebo-controlled, 12-week study.
    Nathan RA, Rooklin A, Schoaf L, Scott C, Ellsworth A, House K, Dorinsky P.
    Clin Ther; 2006 Jan; 28(1):73-85. PubMed ID: 16490581
    [Abstract] [Full Text] [Related]

  • 12. Salmeterol and fluticasone propionate (50/250 microg) administered via combination Diskus inhaler: as effective as when given via separate Diskus inhalers.
    Chapman KR, Ringdal N, Backer V, Palmqvist M, Saarelainen S, Briggs M.
    Can Respir J; 1999 Jan; 6(1):45-51. PubMed ID: 10202220
    [Abstract] [Full Text] [Related]

  • 13. The efficacy and tolerability of inhaled salmeterol and individually dose-titrated, sustained-release theophylline in patients with reversible airways disease.
    Fjellbirkeland L, Gulsvik A, Palmer JB.
    Respir Med; 1994 Sep; 88(8):599-607. PubMed ID: 7991885
    [Abstract] [Full Text] [Related]

  • 14. Nebulized arformoterol in patients with COPD: a 12-week, multicenter, randomized, double-blind, double-dummy, placebo- and active-controlled trial.
    Baumgartner RA, Hanania NA, Calhoun WJ, Sahn SA, Sciarappa K, Hanrahan JP.
    Clin Ther; 2007 Feb; 29(2):261-78. PubMed ID: 17472819
    [Abstract] [Full Text] [Related]

  • 15. [efficacy and safety of salmeterol in long-term therapy in patients with chronic obstructive airway diseases].
    Beeh KM, Wiewrodt R, Salem AE, Buhl R.
    Pneumologie; 2000 Jun; 54(6):225-31. PubMed ID: 10934892
    [Abstract] [Full Text] [Related]

  • 16. The efficacy and safety of salmeterol compared to theophylline: meta-analysis of nine controlled studies.
    Davies B, Brooks G, Devoy M.
    Respir Med; 1998 Feb; 92(2):256-63. PubMed ID: 9616522
    [Abstract] [Full Text] [Related]

  • 17. Tolerability of a salmeterol xinafoate/fluticasone propionate hydrofluoroalkane metered-dose inhaler in adolescent and adult patients with persistent asthma: a 52-week, open-label, stratified, parallel-group, multicenter study.
    Cowie RL, Boulet LP, Keith PK, Scott-Wilson CA, House KW, Dorinsky PM.
    Clin Ther; 2007 Jul; 29(7):1390-402. PubMed ID: 17825690
    [Abstract] [Full Text] [Related]

  • 18. Efficacy of inhaled salmeterol in the management of smokers with chronic obstructive pulmonary disease: a single centre randomised, double blind, placebo controlled, crossover study.
    Ulrik CS.
    Thorax; 1995 Jul; 50(7):750-4. PubMed ID: 7570409
    [Abstract] [Full Text] [Related]

  • 19. Salmeterol xinafoate as maintenance therapy compared with albuterol in patients with asthma.
    D'Alonzo GE, Nathan RA, Henochowicz S, Morris RJ, Ratner P, Rennard SI.
    JAMA; 1994 May 11; 271(18):1412-6. PubMed ID: 7909853
    [Abstract] [Full Text] [Related]

  • 20. Effect on lung function and morning activities of budesonide/formoterol versus salmeterol/fluticasone in patients with COPD.
    Partridge MR, Schuermann W, Beckman O, Persson T, Polanowski T.
    Ther Adv Respir Dis; 2009 Aug 11; 3(4):1-11. PubMed ID: 19734176
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 9.